Site Specific ADC Generation Using SMARTag™ Technology

Summary: Of the >30 ADCs currently in Phase I and II clinical trials, none have site-specific drug placement, despite growing evidence that controlled cytotoxin placement results in a higher tolerated dose and longer efficacy. Catalent is using rational conjugate design with selective drug placement to perform SAR-type studies for improved conjugate stability, reduced systemic toxicity, and enhanced efficacy.

Download the File